Why the study?
Does aspirin plus ticagrelor prevent reticulated platelet-driven aggregation compared to aspirin plus a thienopyridine in patients with stable cardiovascular disease?
Population
Healthy volunteers and patients with stable cardiovascular disease
Comparison
Aspirin plus ticagrelor vs Aspirin plus a thienopyridine (e.g., clopidogrel)
Design
Preclinical
Authors
Loading...
May explain persistent reactivity despite clopidogrel; leaves open whether targeting turnover improves outcomes.
Does aspirin plus ticagrelor prevent reticulated platelet-driven aggregation compared to aspirin plus a thienopyridine in patients with stable cardiovascular disease?
Ticagrelor, due to its longer half-life and circulating inhibitor effect, prevents the aggregation of newly formed reticulated platelets that undermine short-lived antiplatelet therapies like thienopyridines.
Armstrong et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: